Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17645964 | 0.82 | KDM4E (0.62) | ALDH1A1SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL2568384 | 0.78 | SMN1; SMN2 (0.62) | ALDH1A1SMN1; SMN2MAPTKMT2AL3MBTL1 | |
| SCHEMBL28851491 | 0.75 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2KMT2AMEN1TSHR | |
| SCHEMBL17645850 | 0.74 | MAPT (1.00) | ALDH1A1SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL27691790 | 0.74 | GRM2 (0.52) | — | |
| SCHEMBL12077838 | 0.73 | MAPT (0.73) | ALDH1A1SMN1; SMN2MAPTCYP2C19KMT2A | |
| SCHEMBL2565395 | 0.70 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL2565663 | 0.70 | KMT2A (0.67) | ALDH1A1SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL790267 | 0.69 | HTT (0.64) | ALDH1A1SMN1; SMN2MAPTCYP2C19KMT2A | |
| SCHEMBL13571459 | 0.69 | PKM (0.67) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204007-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1 INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| CN-107106546-A | Triazolopyridine compounds and methods for treating cystic fibrosis | 弗拉特利发现实验室有限责任公司 | 2017-08-29 | — | — | CN | disclosed |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2017-08-17 | — | — | US | disclosed |
| EP-3204007-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | Flatley Discovery Lab, LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9573948-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573948-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573948-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB (US) | 2017-02-21 | — | — | US | disclosed |
| WO-2016057522-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057522-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | CFTR, KCNJ11, KCNJ1 | ALDH1A1 507/4885SMN1; SMN2 3936/4885MAPT 4870/4885 |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, KCNJ11, KCNJ1 | ALDH1A1 507/4885SMN1; SMN2 3936/4885MAPT 4870/4885 |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, KCNJ11, KCNJ1 | ALDH1A1 507/4885SMN1; SMN2 3936/4885MAPT 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.